Ignite Creation Date:
2026-03-26 @ 3:16 PM
Ignite Modification Date:
2026-03-30 @ 1:31 AM
Study NCT ID:
NCT07446257
Status:
NOT_YET_RECRUITING
Last Update Posted:
2026-03-03
First Post:
2026-01-29
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
THIO and Cadonilimab in Resectable Hepatocellular Carcinoma
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2026-03-25'}, 'conditionBrowseModule': {'meshes': [{'id': 'D006528', 'term': 'Carcinoma, Hepatocellular'}], 'ancestors': [{'id': 'D000230', 'term': 'Adenocarcinoma'}, {'id': 'D002277', 'term': 'Carcinoma'}, {'id': 'D009375', 'term': 'Neoplasms, Glandular and Epithelial'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D008113', 'term': 'Liver Neoplasms'}, {'id': 'D004067', 'term': 'Digestive System Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}, {'id': 'D008107', 'term': 'Liver Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C002062', 'term': "alpha-2'-deoxythioguanosine"}]}}, 'protocolSection': {'designModule': {'phases': ['EARLY_PHASE1'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 60}}, 'statusModule': {'overallStatus': 'NOT_YET_RECRUITING', 'startDateStruct': {'date': '2026-05-01', 'type': 'ESTIMATED'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2026-02', 'completionDateStruct': {'date': '2031-05-01', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2026-02-25', 'studyFirstSubmitDate': '2026-01-29', 'studyFirstSubmitQcDate': '2026-02-25', 'lastUpdatePostDateStruct': {'date': '2026-03-03', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2026-03-03', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2030-05-01', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Incidence of treatment-related delay of surgical resection >28 days from expected surgery date.', 'timeFrame': '28 days after the expected surgery date (day 5 of cycle 3 for all treatment arms)', 'description': 'Safety is measured as the proportion of participants who experience a treatment-related delay in the planned surgical resection, defined as surgery occurring more than 28 days after the expected surgery date (day 5 of cycle 3 for all treatment arms)'}], 'secondaryOutcomes': [{'measure': 'Pathologic response of ateganosine plus cadonilimab', 'timeFrame': 'Day 1 of treatment up to surgery resection', 'description': 'Response will be determined by pathology review of resection specimens and will be based on \\<30% residual viable tumor in the tumor bed at the time of surgery.'}, {'measure': 'Radiographic response after ateganosine plus cadonilimab', 'timeFrame': 'Baseline to between day 2-4 of the last cycle immediately prior to surgery', 'description': 'Radiographic response will be based on changes in only the largest diameter (unidimensional measurement) of the tumor lesions per the RECIST v1.1 criteria.'}, {'measure': 'Survival outcomes after ateganosine plus cadonilimab', 'timeFrame': 'first dose of drug (whichever was last) up to 36 months until death, loss to follow-up, or until study termination by the Sponsor.', 'description': 'Overall survival (measured as time from the first dose of study treatment to death from any cause)'}, {'measure': 'Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]', 'timeFrame': 'post last dose visit up to 3 years until death, loss to follow-up, or until study termination by the Sponsor.', 'description': 'Incidence of treatment emergent adverse events (AEs), immune-related AEs, and serious AEs (Grade ≥3 per Common Terminology Criteria for Adverse Events, CTCAE v5.0).'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['liver', 'hepatocellular carcinoma'], 'conditions': ['Resectable Hepatocellular Carcinoma']}, 'descriptionModule': {'briefSummary': 'The goal of this clinical study is to find out if cadonilimab or ateganosine plus cadonilimab is effective and safe in treating resectable hepatocellular carcinoma (HCC).', 'detailedDescription': "In this study, ateganosine (also know as THIO, 6-thio-dG, 6-thio-2'-deoxyguanosine) and cadonilimab are given via intravenous infusion. The participant will be randomly assigned to receive cadonilimab alone, ateganosine alone, or ateganosine and cadonilimab.\n\nFor this study, a cycle is defined as 21 calendar days during which drugs are administered.\n\nIf the participant is randomized to the cadonilimab alone arm, infusions will be given on the first day of every 21-day cycle. The participant will receive 2 doses of cadonilimab and then be evaluated for surgery.\n\nIf the participant is randomized to be treated with ateganosine alone, infusions of ateganosine will be given on days 1 to 3 of every 21-day cycle for 3 cycles and then the participant will be evaluated for surgery.\n\nIf the participant is randomized to be treated with ateganosine and cadonilimab, infusions of ateganosine will be given on days 1 to 3 of every 21-day cycle for 3 cycles. Infusions of cadonilimab will be given on day 5 of every 21-day cycle for 2 cycles. After receiving 3 cycles of ateganosine and 2 cycles of cadonilimab, the participant will be evaluated for surgery."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n1. Diagnosis of HCC confirmed by histology or according to the American Association for the Study of Liver Disease (AASLD) criteria\n\n a. Availability of tumor tissue samples prior to the first day of study treatment is required for all patients.\n2. HCC that is amenable to R0 resection with curative intent as determined by treating surgical/medical oncologists in consultation with the principal investigator. Subject must be a suitable candidate for surgery based on evaluations by the treating surgeon/oncologist.\n3. Measurable disease according to RECIST 1.1\n4. No prior anti-PD (Programmed death)-1/L1 therapies for any indication\n5. Age ≥18\n6. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1\n7. Child Pugh A\n8. Adequate organ and marrow function as defined below:\n\n 1. ANC (absolute neutrophil count) ≥ 1.5 x 109/L (does not apply to patients with benign ethnic neutropenia)\n 2. Platelets ≥ 75 x 109/L without transfusion\n 3. Hemoglobin ≥ 9 g/dL without transfusion within 2 weeks of screening\n 4. ALT (Alanine Aminotransferase) ≤ 3 2 x ULN (Upper Limit of Normal)\n 5. Bilirubin ≤ 3 x ULN\n 6. Creatinine clearance ≥ 50 mL/min calculated by the Cockcroft-Gault formula using actual body weight\n9. All etiologies of chronic liver disease including but not limited to Hepatis C Virus (HCV) or Hepatis B Virus (HBV) infection. HCV and HBV infection status does not preclude eligibility as long as patients meet all other eligibility criteria but must be known prior to starting treatment. Patients with HBV must be on anti-viral therapy prior to the first day of investigational drug treatment. Patients with HCV may include active or resolved infection.\n10. All men, as well as women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 3 months following the last dose of ateganosine or 4 months following the last dose of cadonilimab. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.\n\n A female of child-bearing potential is any woman (regardless of sexual orientation, marital status, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:\n * Has not undergone a hysterectomy or bilateral oophorectomy; or\n * Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).\n11. Ability to understand and the willingness to sign a written informed consent.\n12. Willing and able to comply with the requirements and restrictions in this protocol.\n\nExclusion Criteria:\n\n1. Presence of extrahepatic extension of disease\n2. Prior locoregional therapy to target lesions is not allowed. History of curative locoregional therapy is allowed provided the following are met: 1) previously treated tumor is not viable without evidence of residual disease for at least 12 months, and 2) patient has not received local therapy in the past 12 months.\n3. Known fibrolamellar HCC or combined HCC-cholangiocarcinoma histology\n4. History of hepatic encephalopathy\n5. Severe ascites requiring paracentesis in the past 3 months\n6. Subjects may not be receiving any other investigational agents for the treatment of the cancer under study\n7. Prior significant bleeding event in the past 3 months that may pose a surgical risk\n8. History of trauma or major surgery within 28 days prior to the first dose of study drug administration. (Tumor biopsy or placement of central venous access catheter (eg, port or similar) is not considered a major surgical procedure)\n9. Underlying medical conditions that, in the investigator's opinion, will make the administration of study drugs hazardous, including but not limited to:\n\n 1. Autoimmune interstitial lung disease (lymphangitic spread of cancer is not disqualifying or stable/chronic lung disease that is not likely to be autoimmune in nature and progressive),\n 2. Active viral, bacterial, or fungal infections requiring parenteral treatment within 14 days of the initiation of study drugs,\n 3. Clinically significant cardiovascular disease,\n 4. A condition that may obscure the interpretation of toxicity determination or AEs,\n 5. History of prior bone marrow and/or solid-organ transplantation\n10. Hypersensitivity to IV contrast; not suitable for pre-medication\n11. Any active autoimmune disease or a documented history of autoimmune disease or syndrome that required systemic treatment in the past year (ie, with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs), with the following exceptions:\n\n 1. Autoimmune diseases with only dermatologic involvement such as eczema, vitiligo, lichen chronicus, or resolved childhood asthma/atopy which involves less than 10% of the body surface area and symptoms are well controlled on topical treatments without recent exacerbations requiring other therapies\n 2. Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for thyroid, adrenal or pituitary insufficiency) is not considered a form of systemic treatment\n 3. Participants with asthma who require intermittent use of bronchodilators, inhaled corticosteroids, or local corticosteroid injections will not be excluded from this study\n12. Subjects with a condition requiring systemic treatment with either corticosteroids (\\> 10 mg/day prednisone equivalent) or other immunosuppressive medications within 14 days of study administration. Inhaled or topical steroids and adrenal replacement doses ≤10 mg/day prednisone equivalents are permitted in the absence of autoimmune disease.\n13. Prior malignancy that required systemic treatment within the previous 2 years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix, breast, or prostate cancer. Patients with a cancer history with a low risk of recurrence or progression may be enrolled as determined by the principal investigator.\n14. Prisoners or subjects who are involuntarily incarcerated\n15. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after contraception and until the termination of gestation, confirmed by a positive hCG (Human chorionic gonadotropin) laboratory test\n16. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial\n17. Evidence of bleeding diathesis or significant coagulopathy\n18. Current use of full dose anticoagulant use which cannot be temporarily discontinued for surgery\n19. Receipt of live vaccinations within 30 days of first treatment day"}, 'identificationModule': {'nctId': 'NCT07446257', 'briefTitle': 'THIO and Cadonilimab in Resectable Hepatocellular Carcinoma', 'organization': {'class': 'OTHER', 'fullName': 'University of Texas Southwestern Medical Center'}, 'officialTitle': 'A Phase Ib Open-label, Randomized Trial Evaluating Neoadjuvant Ateganosine and Cadonilimab in Resectable Hepatocellular Carcinoma', 'orgStudyIdInfo': {'id': 'SCCC-12225; STU20251351'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Arm A: Ateganocine + Cadonilimab', 'description': 'Ateganosine: 60 mg/day (180 mg/cycle) IV over 30 minutes±5 minutes Cadonilimab: 10 mg/kg IV over 60 minutes±5 minutes', 'interventionNames': ['Drug: ateganosine', 'Drug: Cadonilimab']}, {'type': 'EXPERIMENTAL', 'label': 'Arm B: Ateganocine', 'description': 'Ateganosine: 60 mg/day (180 mg/cycle) IV over 30 minutes±5 minutes', 'interventionNames': ['Drug: ateganosine']}, {'type': 'EXPERIMENTAL', 'label': 'Arm C: Cadonilimab', 'description': 'Cadonilimab: 10 mg/kg IV over 60 minutes±5 minutes', 'interventionNames': ['Drug: Cadonilimab']}], 'interventions': [{'name': 'ateganosine', 'type': 'DRUG', 'otherNames': ["THIO, 6-thio-dG, 6-thio-2'-deoxyguanosine"], 'description': 'ateganosine: 180 mg IV D1, D2, D3 of 21-day cycle', 'armGroupLabels': ['Arm A: Ateganocine + Cadonilimab', 'Arm B: Ateganocine']}, {'name': 'Cadonilimab', 'type': 'DRUG', 'otherNames': ['AK104 (or AK-104)'], 'description': 'cadonilimab: 10 mg/kg IV D5 of 21-day cycle', 'armGroupLabels': ['Arm A: Ateganocine + Cadonilimab', 'Arm C: Cadonilimab']}]}, 'contactsLocationsModule': {'locations': [{'zip': '75390', 'city': 'Dallas', 'state': 'Texas', 'country': 'United States', 'contacts': [{'name': 'Carrie Manwaring', 'role': 'CONTACT', 'email': 'carrie.manwaring@utsouthwestern.edu', 'phone': '214-648-7097'}, {'name': 'David Hsieh, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'University of Texas Southwestern Medical Center', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}], 'centralContacts': [{'name': 'Carrie Manwaring', 'role': 'CONTACT', 'email': 'carrie.manwaring@utsouthwestern.edu', 'phone': '214-648-7097'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'University of Texas Southwestern Medical Center', 'class': 'OTHER'}, 'collaborators': [{'name': 'Maia Biotechnology', 'class': 'INDUSTRY'}, {'name': 'National Cancer Institute (NCI)', 'class': 'NIH'}], 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'ASSOC PROFESSOR • Internal Medicine', 'investigatorFullName': 'David Hsieh', 'investigatorAffiliation': 'University of Texas Southwestern Medical Center'}}}}